AMINOSYN II 8.5% W/ ELECTROLYTES Drug Patent Profile
Which patents cover Aminosyn Ii 8.5% W/ Electrolytes, and when can generic versions of Aminosyn Ii 8.5% W/ Electrolytes launch?
Aminosyn Ii 8.5% W/ Electrolytes is a drug marketed by Icu Medical Inc and is included in one NDA.
The generic ingredient in AMINOSYN II 8.5% W/ ELECTROLYTES is amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride. There is one drug master file entry for this compound. Additional details are available on the amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AMINOSYN II 8.5% W/ ELECTROLYTES?
- What are the global sales for AMINOSYN II 8.5% W/ ELECTROLYTES?
- What is Average Wholesale Price for AMINOSYN II 8.5% W/ ELECTROLYTES?
Summary for AMINOSYN II 8.5% W/ ELECTROLYTES
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | AMINOSYN II 8.5% W/ ELECTROLYTES at DailyMed |
US Patents and Regulatory Information for AMINOSYN II 8.5% W/ ELECTROLYTES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Icu Medical Inc | AMINOSYN II 8.5% W/ ELECTROLYTES | amino acids; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride | INJECTABLE;INJECTION | 019437-005 | Apr 3, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Aminosyn II 8.5% With Electrolytes: Market Dynamics, Exclusivity and Financial Trajectory
Aminosyn II 8.5% with Electrolytes is a mature parenteral nutrition product used to provide amino acids and electrolytes when oral or enteral nutrition is inadequate or contraindicated. Its commercial profile is driven by hospital demand, sterile injectable manufacturing capacity, supply availability and contract pricing rather than patent exclusivity. Public sources do not disclose standalone revenue for Aminosyn II, and the product does not have a visible blockbuster-style patent or exclusivity profile.
What is Aminosyn II 8.5% With Electrolytes?
Aminosyn II 8.5% with Electrolytes is an intravenous amino acid solution used as part of parenteral nutrition. The formulation supplies crystalline amino acids together with electrolytes and is administered through a central venous route when the solution's osmolarity requires it. It may be combined with dextrose, lipid emulsions, vitamins, trace elements and other components of total parenteral nutrition.
The product belongs to the mature amino acid injection segment, which includes:
- Aminosyn and Aminosyn II products
- Travasol amino acid injections
- Clinimix premixed amino acid and dextrose products
- TrophAmine pediatric amino acid injections
- ProcalAmine peripheral amino acid injections
- Hospital-compounded parenteral nutrition preparations
Aminosyn II is not a biologic. Biosimilar competition is therefore not relevant. The relevant competitors are generic or therapeutically substitutable sterile injectable amino acid products.
Product and clinical characteristics
| Attribute | Aminosyn II 8.5% With Electrolytes |
|---|---|
| Active components | Crystalline amino acids and electrolytes |
| Dosage form | Sterile intravenous solution |
| Therapeutic category | Parenteral nutrition |
| Primary customers | Hospitals, health systems, specialty pharmacies and distributors |
| Primary use | Nutritional support when oral or enteral feeding is inadequate |
| Administration | Intravenous, generally through a central venous route |
| Regulatory category | Mature prescription injectable product |
| Biosimilar exposure | Not applicable |
| Commercial differentiation | Limited; supply reliability and contract price are more important than branding |
The FDA-approved labeling identifies the product as a component of parenteral nutrition rather than a stand-alone treatment for a specific disease [1].
Who manufactures Aminosyn II and how is the product sold?
Aminosyn II has been associated with the hospital injectable and parenteral nutrition portfolios of large sterile-product manufacturers. Product ownership, labeler status and commercial availability can vary by package size, National Drug Code and manufacturing site. DailyMed should be used to verify the current labeler and package-specific status because labels and marketing arrangements can change without a new clinical development program [1].
The product is typically sold through:
- Direct hospital and health-system contracts.
- Group purchasing organization agreements.
- Pharmaceutical wholesalers and specialty distributors.
- Institutional pharmacy procurement systems.
- Emergency and shortage-driven purchasing channels.
The purchasing decision is usually made at the formulary, pharmacy and supply-chain level. Physicians have less influence over brand selection than in outpatient specialty medicines because hospitals can often substitute among amino acid solutions if the formulation, concentration, electrolyte profile and route of administration are acceptable.
What is the market size for Aminosyn II 8.5% With Electrolytes?
No reliable public source reports standalone global or U.S. revenue for Aminosyn II 8.5% with Electrolytes. Manufacturers generally report hospital injectables, nutrition products or established pharmaceutical portfolios in aggregate rather than disclosing sales by individual amino acid solution.
The addressable market is the broader parenteral nutrition market, not the Aminosyn II brand alone. Demand is linked to:
- Intensive-care admissions
- Major surgery
- Oncology treatment
- Gastrointestinal failure
- Short-bowel syndrome
- Severe malnutrition
- Neonatal and pediatric nutrition
- Critical illness requiring prolonged nutritional support
Revenue growth is constrained by the mature nature of the product. Unit demand can rise with hospital utilization, but pricing is generally pressured by tenders, generic substitution and purchasing-group negotiations.
Revenue exposure and financial visibility
| Financial factor | Effect on Aminosyn II |
|---|---|
| Standalone revenue disclosure | Generally unavailable |
| Pricing power | Low to moderate |
| Volume sensitivity | Tied to hospital utilization and parenteral nutrition demand |
| Margin sensitivity | High exposure to manufacturing, labor, container and freight costs |
| Contract duration | Often governed by institutional and purchasing-group agreements |
| Inventory economics | Sensitive to shelf life and shortage-related stockpiling |
| Growth profile | Mature, low-growth or volume-led |
| Main upside driver | Supply continuity during competitor shortages |
| Main downside driver | Contract loss, substitution or manufacturing interruption |
A manufacturer can experience a temporary revenue increase if competitors face production problems. That increase may not represent durable market-share expansion because hospitals often return to prior suppliers once supply normalizes.
When does Aminosyn II lose exclusivity?
Aminosyn II is a mature injectable product, and its commercial position does not appear to depend on an active period of new-drug exclusivity. Public FDA resources do not indicate a conventional market-exclusivity timeline comparable to a recently approved small-molecule drug [2][3].
The relevant commercial question is therefore not when exclusivity expires. It is whether competitors can obtain or maintain approval, production capacity and distribution for a therapeutically substitutable amino acid injection.
Patent and exclusivity assessment
| Protection category | Assessment |
|---|---|
| New chemical entity exclusivity | Not relevant to this mature amino acid formulation |
| Orphan-drug exclusivity | Not identified |
| Pediatric exclusivity | Not identified |
| Orange Book patent protection | No prominent product-specific patent estate identified in public FDA resources |
| Formulation patents | Any historic protection would likely be expired or commercially limited |
| Method-of-use patents | Unlikely to provide meaningful protection for routine nutritional support |
| Manufacturing patents | Potentially relevant to production efficiency, container systems or aseptic processing, but not necessarily product-specific |
| Biosimilar exclusivity | Not applicable |
The absence of a meaningful patent barrier does not guarantee immediate competitive entry. Sterile injectable manufacturing requires validated facilities, aseptic controls, container-closure systems, quality systems and reliable component supply.
What is the Orange Book status of Aminosyn II?
Aminosyn II does not present the typical Orange Book strategy seen with branded small-molecule medicines. The Orange Book is most important where a reference listed drug has unexpired patents or regulatory exclusivity that can support Paragraph IV litigation. Amino acid injections are generally commercialized as established injectable products where approval and manufacturing capacity matter more than patent fencing [3].
A prospective competitor would need to evaluate:
- The specific reference product and NDC
- The applicable FDA approval pathway
- Whether an ANDA or another application type is appropriate
- Formulation equivalence
- Electrolyte composition
- Container and administration requirements
- Sterility and particulate specifications
- Labeling and clinical-use restrictions
- Any listed patents associated with the relevant reference product
Which companies are challenging Aminosyn II?
No major public Paragraph IV challenge or branded patent litigation campaign targeting Aminosyn II is evident from the public FDA and court-record framework generally used for Orange Book disputes. Competitive pressure is more likely to come from manufacturers of alternative amino acid injections and premixed parenteral nutrition products than from a single high-profile patent challenger.
Potential competitive groups include:
- Large hospital-injectable manufacturers
- Generic sterile injectable companies
- Parenteral nutrition specialists
- Contract manufacturers with validated aseptic capacity
- Hospital pharmacies that compound individualized nutrition solutions
The principal competitors are not necessarily direct substitutes. Clinimix products, for example, combine amino acids with dextrose and may replace a separately sourced amino acid solution in some hospital protocols. Travasol and other amino acid injections may be closer formulation substitutes, subject to concentration and electrolyte differences.
What formulation patents protect Aminosyn II?
No current, commercially decisive formulation patent estate is apparent for Aminosyn II 8.5% with Electrolytes. The formulation consists of conventional amino acids and electrolytes in an intravenous solution. Historic patents, if any, would face substantial age-related expiration risk because Aminosyn products have been marketed for decades.
Potential technical protection could relate to:
- Specific amino acid ratios
- Electrolyte concentrations
- pH and buffering
- Stability during storage
- Container-closure systems
- Overwrap and oxygen-control systems
- Manufacturing and sterilization procedures
- Compatibility with parenteral nutrition admixtures
These features can create regulatory and operational barriers without creating strong exclusionary patent rights. A competitor may be able to design around a formulation claim while still needing extensive stability, sterility and compatibility data.
How strong is the patent estate for Aminosyn II?
The patent estate is likely weak as a commercial defense. The product's durability depends on execution rather than exclusivity.
Patent-strength scorecard
| Factor | Commercial assessment |
|---|---|
| Composition-of-matter protection | Very low relevance |
| Active formulation patents | Limited evidence of current protection |
| Method-of-use protection | Low |
| Manufacturing know-how | Potentially meaningful but difficult to measure publicly |
| Regulatory approval barrier | Moderate |
| Sterile manufacturing barrier | Moderate to high |
| Switching costs | Moderate in hospital systems |
| Brand differentiation | Low |
| Overall patent-based defense | Weak |
| Overall supply-based defense | More important than patent protection |
A supplier with an established manufacturing network, reliable raw-material sourcing and a strong hospital-contract footprint may retain share despite limited patent protection.
What FDA regulatory issues affect Aminosyn II?
FDA risk is concentrated in manufacturing quality, product availability and labeling compliance. The product is an injectable sterile solution, so manufacturing failures can have immediate commercial effects.
Key FDA-related risks include:
- Aseptic processing deviations
- Visible or subvisible particulate contamination
- Endotoxin or sterility failures
- Container-closure defects
- Incorrect electrolyte concentration
- Labeling errors
- Stability failures
- Manufacturing-site inspections
- Product recalls
- Drug shortages or constrained supply
FDA drug-shortage data is material to the product's financial trajectory. A shortage involving one supplier can redirect hospital demand to another supplier, while a shortage across the category can reduce treatment capacity and force hospitals to compound nutrition products or alter protocols [4].
What generic entry risks exist for Aminosyn II?
Generic-entry risk is structurally high because the product is mature and has limited brand differentiation. The risk is moderated by the technical difficulty of sterile injectable production.
High-probability competitive scenarios
Scenario 1: Stable multi-supplier competition.
Multiple suppliers maintain approval and adequate capacity. Prices remain under pressure, and market share follows contract awards, availability and wholesaler coverage.
Scenario 2: Supply-constrained pricing.
One or more manufacturers experience a shortage, recall or site interruption. Remaining suppliers gain temporary volume and may improve net pricing.
Scenario 3: Formulary substitution.
Hospitals substitute another amino acid concentration or a premixed product. Aminosyn II unit volume declines even if total parenteral nutrition demand remains stable.
Scenario 4: Compounding substitution.
Large hospitals or compounding pharmacies prepare individualized parenteral nutrition formulations, reducing demand for standardized products.
The most credible long-term risk is gradual substitution rather than an abrupt patent-triggered generic launch.
What patent litigation and settlement agreements affect Aminosyn II?
No significant publicly documented patent litigation or settlement agreement appears to define the current commercial position of Aminosyn II. Paragraph IV settlements are more common for branded drugs with active Orange Book patents, pediatric formulations or major therapeutic markets. A mature amino acid injection generally offers less economic incentive for high-value patent litigation.
Potential disputes would more likely involve:
- Product-quality claims
- Manufacturing contracts
- Supply agreements
- Hospital procurement contracts
- Recall-related liability
- Regulatory approval or labeling issues
- Trade secrets involving sterile manufacturing
This litigation profile differs sharply from products protected by multiple formulation, dosing and method-of-use patents.
How does Aminosyn II compare with competing parenteral nutrition products?
| Product category | Competitive relationship | Commercial implication |
|---|---|---|
| Travasol amino acid injection | Close substitute | Direct price and availability competition |
| Clinimix premixed solution | Partial substitute | Can reduce demand for separately purchased amino acids and dextrose |
| TrophAmine | Segment-specific substitute | Stronger relevance in neonatal and pediatric care |
| ProcalAmine | Route and use differentiated | May substitute where peripheral administration is clinically appropriate |
| Customized compounded PN | Functional substitute | Increases flexibility but adds pharmacy labor and quality requirements |
| Lipid-containing PN products | Complement or alternative regimen | Changes total nutrition-product purchasing patterns |
Aminosyn II competes most directly on concentration, electrolyte composition, compatibility, availability and contract price. Clinical switching requires pharmacy review because amino acid concentration and electrolyte content affect the final parenteral nutrition regimen.
What licensing deals affect Aminosyn II?
No major publicly disclosed licensing transaction appears to have been built around Aminosyn II 8.5% with Electrolytes as an individual asset. Commercial arrangements are more likely to involve broader hospital-injectable portfolios, manufacturing transfers, distribution rights or supply contracts.
The financial significance of a transaction would depend on whether it transfers:
- The approved product application
- Manufacturing rights
- Product trademarks
- NDC and labeler rights
- Existing hospital contracts
- Inventory and distribution obligations
- Manufacturing-site capacity
- Quality and pharmacovigilance responsibilities
A product transfer can alter market availability without changing the underlying clinical product.
What is the financial trajectory for Aminosyn II?
The expected trajectory is mature and operationally sensitive.
Base case
Revenue remains stable to modestly declining in nominal terms. Volume follows hospital utilization, while net price is pressured by institutional contracts and alternative products. Profitability depends on manufacturing efficiency and the ability to avoid quality events or supply interruptions.
Upside case
A competitor experiences a prolonged shortage, recall or manufacturing interruption. Aminosyn II gains temporary share and may generate higher revenue through increased unit volume. The benefit is likely reversible when competitors restore supply.
Downside case
A hospital system moves to a competing amino acid product, Clinimix or compounded nutrition. Contract loss combines with price erosion, reducing volume and contribution margin. A manufacturing or quality event would amplify the decline.
Financial indicators to monitor
- FDA drug-shortage status
- Product discontinuation notices
- NDC activity and package availability
- Hospital contract awards
- Wholesale inventory
- Manufacturing-site inspection outcomes
- Recall or warning-letter activity
- Parent-company hospital injectable revenue
- Changes in parenteral nutrition utilization
- Competitor capacity additions
Key Takeaways
- Aminosyn II 8.5% with Electrolytes is a mature intravenous amino acid product used in parenteral nutrition.
- Its commercial value depends more on supply reliability, sterile manufacturing and hospital contracts than on patent exclusivity.
- No material current Orange Book patent barrier or active Paragraph IV litigation strategy is apparent.
- Biosimilar competition does not apply because the product is not a biologic.
- Generic and therapeutic-substitution risk is high, but sterile injectable manufacturing limits the speed of competitive entry.
- Standalone revenue is not publicly disclosed, so the product's financial trajectory must be assessed through market, supply and parent-company portfolio data.
- The most likely base case is stable to modestly declining revenue, with temporary upside during competitor shortages.
- Formulation know-how, validated manufacturing and distribution reach are more important defenses than patents.
FAQs
Is Aminosyn II 8.5% with Electrolytes still available?
Availability can vary by NDC, package size, supplier and distribution channel. FDA shortage information and current DailyMed labeling are the primary public sources for status verification [1][4].
Is Aminosyn II a generic drug?
It is a mature hospital injectable product competing in a generic-like market. The commercial category includes multiple amino acid injections and parenteral nutrition alternatives.
Does Aminosyn II have biosimilar competition?
No. Biosimilar rules apply to biologic products. Aminosyn II is a sterile amino acid solution.
Can Clinimix replace Aminosyn II?
Clinimix can be a partial substitute because it combines amino acids and dextrose. Substitution depends on the patient's nutrition plan, electrolyte requirements, pharmacy protocol and route of administration.
What is the main investment risk for an Aminosyn II supplier?
The main risks are contract-driven price erosion, competitor substitution, sterile manufacturing interruptions, recalls, shortages and loss of hospital purchasing volume. Patent expiry is not the primary risk.
References
-
National Library of Medicine. (n.d.). DailyMed: Aminosyn II 8.5% with electrolytes labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). FDA drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
More… ↓
